Landmark Study Uncovers Limits of Repeated Cloning in Mammals

A groundbreaking 20-year experiment has finally answered a long-standing question in reproductive biology: can mammals be cloned indefinitely? Researchers at the University of Yamanashi in Japan pushed the boundaries of somatic cell nuclear transfer (SCNT), the technique famously used to create Dolly the sheep, by serially cloning mice from a single female donor. The results, published recently, reveal that genetic mutations accumulate rapidly, rendering further cloning impossible after just 25 viable generations.

This study not only highlights the fragility of asexual reproduction in mammals but also has profound implications for biotechnology research worldwide, including in Singapore's thriving higher education sector where stem cell and gene editing technologies are advancing rapidly.

History and Evolution of Mammalian Cloning Techniques

Mammalian cloning via SCNT involves taking the nucleus from a somatic (body) cell and inserting it into an enucleated oocyte (egg cell), then stimulating it to develop into an embryo. Teruhiko Wakayama's team pioneered mouse cloning in 1998, a feat that overcame earlier failures in mammals due to imprinting errors and mitochondrial incompatibilities.

Over the years, improvements allowed cloning from frozen tissues and even intestinal cells. However, serial recloning—cloning clones repeatedly—had only reached six generations previously. This experiment extended it dramatically, producing 1,206 cloned mice over 58 'generations' through more than 30,000 attempts.

In Singapore, universities like the National University of Singapore (NUS) and Nanyang Technological University (NTU) have contributed to cloning-adjacent fields, focusing on induced pluripotent stem cells (iPSCs) as ethical alternatives to embryo-derived cloning.

Detailed Methodology of the Serial Cloning Experiment

Starting in 2005 with a single donor mouse, the Japanese team harvested cumulus cells (surrounding ovarian follicles) for nuclear transfer into enucleated oocytes from B6D2F1 mice. Embryos were cultured in vitro and transferred to pseudopregnant recipients.

Success rates remained high until generation 25, with clones maturing normally and producing offspring. Post-generation 25, litter sizes dropped, and by generation 58, pups died within days despite normal appearance. Genome sequencing showed mutations tripling compared to sexually reproduced mice.

• Generations 1-25: Normal development, fertility, lifespan.
• Generations 26-57: Declining viability, smaller litters.
• Generation 58: Lethal, multiple organ failures.

Accumulation of Genetic Mutations: The Core Discovery

The study identified large-scale structural variants (SVs), including copy number variations and chromosomal aneuploidy, like X chromosome loss in females. Single nucleotide variants (SNVs) also surged. These 'mutational meltdown' effects lack the purifying selection of sexual reproduction, where meiosis shuffles genes and deleterious mutations are purged.

In asexual lineages, all mutations propagate, akin to photocopying a photocopy repeatedly until illegible. For more on the paper, see the full study here.

Biological Mechanisms Driving Mutation Buildup

SCNT stresses nuclear reprogramming, causing epigenetic errors and DNA damage. Repeated cycles amplify this, leading to telomere shortening, mitochondrial dysfunction, and replication errors. Without recombination, Muller's ratchet—irreversible mutation accumulation in asexual populations—turns.

This explains why plants (polyploid, self-fertile) clone indefinitely, but mammals cannot. Implications extend to conservation: cloning endangered species risks genetic dead ends without diverse founders.

Global Biotech Implications and Agricultural Challenges

For livestock cloning (e.g., elite cows), serial use is limited; sexual breeding remains essential. In pharma, iPSCs bypass cloning pitfalls for drug screening. The study underscores CRISPR's rise for precise edits over cloning. Nature commentary highlights preservation needs genetic diversity.

Singapore's Position in Stem Cell and Gene Editing Research

Singapore invests S$25B+ in RIE2025 for biotech, with A*STAR, NUS, NTU leading. While reproductive cloning is banned under the Human Cloning Act, therapeutic SCNT and iPSCs thrive. NUS's Transgenic Facility uses CRISPR for mouse knockouts, modeling diseases without serial cloning risks.

NTU's stem cell labs develop iPS-derived therapies, echoing Yamanaka's Nobel-winning work (Japanese, but inspirational locally).

Key Initiatives at Singapore Universities

NUS CSI's Gene Targeting Facility generates CRISPR-edited mice for cancer, neuro research—safer than cloning. Duke-NUS (with NUS) SCAGE core advances iPS/CRISPR for clinical translation. NTU collaborates on iPSC manufacturing with A*STAR/SCG Cell Therapy.

• A*STAR's SIgN: Immunology via gene-edited models.
• NTU RNA hub: S$130M for therapeutics, avoiding cloning ethics.
• NUS iPS research: Patient-specific cells sans embryos.

These position Singapore unis as Asia's biotech hubs. For details, CNA coverage.

Career Opportunities in Singapore's Biotech Sector

With 40,000+ biotech jobs projected, unis offer PhDs/MSc in repro genetics. Roles in CRISPR labs, iPSC production at A*STAR. Salaries average S$60k starting for researchers.

Programs like NUS PhD (Biomedical Sciences) train on mutation analysis, vital post-this study.

Photo by ynov . on Unsplash

Future Outlook: Beyond Cloning to Precision Genetics

The study reinforces shift to gene editing. Singapore's S$800M decarbonisation/biotech funds support sustainable repro tech. Outlook: Hybrid approaches combining iPS, CRISPR for 'designer' genetics without mutation traps.

Stakeholders: Ethical BAC oversees; unis collaborate Japan on iPS.